Endo acquires HealthTronics

NewsGuard 100/100 Score
Jul 15 2010

Endo Pharmaceuticals (Nasdaq: ENDP) announced today the completion of its acquisition of HealthTronics, Inc. (Nasdaq: HTRN), a leading U.S. provider of urological products and services, located in Austin, Texas.

On July 12, 2010, Endo acquired HealthTronics through a tender offer and subsequent merger upon which HealthTronics became a wholly owned subsidiary of Endo.  

"The HealthTronics acquisition marks an important step forward in Endo's strategy to diversify beyond pharmaceuticals and solidifies Endo's commitment to the field of Urology," said Dave Holveck, president and CEO of Endo. "Urology practices, the patients they serve and payers will all benefit from the integration of Endo and HealthTronics through our combined expertise, products and services."

SOURCE Endo Pharmaceuticals

Posted in:

Tags: , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Oral spray-based vaccine is a potential alternative to antibiotic treatments for recurrent UTIs
Simple urine test halves cystoscopy procedures for bladder cancer patients
Cancer risk elevated in families with male infertility
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels
Blood-based DNA test spares bladder cancer patients from unnecessary treatments
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis
Researchers find new clues to understanding the progression of primary membranous nephropathy
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Common HIV drugs linked to reduced Alzheimer's disease risk